carl_compliance said:

The dose-response is real but shallow at the top.

Thank you — that is the clearest version of this I have read, and I have read a lot of them. Taking it to my next appointment.

Adding the clinical framing, because it changes how the question reads.

Insurance coverage hack for cost and coverage: if your insurance denies brand Wegovy/Ozempic, consider these alternatives:

1. Prior authorization appeal with peer-to-peer review
2. Manufacturer copay card (for commercial insurance)
3. Patient assistance programs (Novo Nordisk, Eli Lilly)
4. Compounded medication from a 503B pharmacy ($121/month)
5. Canadian pharmacy (requires prescription, ~40-60% savings)

Don't let cost prevent access to effective treatment. There are options at every price point.

TinaHashiRN said:

The mechanism that matters here is not stomach emptying, it is central.

This is where I part company with the consensus forming above. The trial means are being read too generously in this thread. STEP populations were selected, supported, and titrated by protocol, and the real-world curves are consistently a few points worse. That difference is not noise, it is what happens when you remove the study infrastructure.

roxy_nash said:

Denials are usually procedural rather than clinical, and the order that works reflects that.

Financial impact of cost and coverage weight loss beyond medication cost:

• Groceries: SAVED $268/month (eating less)
• Restaurants: SAVED $198/month (fewer meals out)
• Alcohol: SAVED $148/month (stopped drinking)
• Life insurance: Premium REDUCED by $38/month (lower BMI)
• Copays: SAVED $78/month (fewer BP/cholesterol meds)

Net impact after medication cost: approximately BREAKING EVEN. The medication pays for itself through reduced food spending and healthcare costs. This surprised me.

Moderator note: a post naming a supplier has been edited. Discuss suppliers in the review sections, not here. Thread quality here is what the rules are for. Keep it up.